Background
Drostanolone was developed in the mid-20th century and marketed under brand names including Masteron and Permastril. It was investigated for hormone-responsive advanced breast cancer on the basis that androgenic activity could antagonize estrogen-driven tumor growth. Its medical use declined as selective estrogen receptor modulators, aromatase inhibitors, and other targeted therapies became standard of care. Drostanolone is now encountered primarily in non-medical performance and physique contexts. It is a controlled substance in many countries and is included on WADA's prohibited list, meaning possession and use without a prescription carry legal and sporting-eligibility consequences.
Evidence snapshot
Drostanolone is a synthetic androgen derived from dihydrotestosterone. Medical literature on it is limited and mostly historical: it was studied for hormone-responsive breast cancer therapy, but modern oncology rarely uses it given the availability of superior endocrine agents. No contemporary high-quality randomized trials exist for approved indications.
Most current evidence on Masteron derives from the broader anabolic-androgenic steroid (AAS) literature, which documents short-term anabolic effects alongside consistent harms: suppression of endogenous testosterone production, adverse lipid changes, cardiovascular effects, psychiatric effects, and androgenic side effects. This evidence base consists primarily of observational studies, cohort analyses, case reports, and reviews rather than drostanolone-specific controlled trials.
Because drostanolone is non-aromatizable, it does not convert to estrogen, which lowers the risk of estrogenic gynecomastia compared with aromatizable androgens. This does not eliminate cardiovascular, reproductive, or psychiatric risks. Legal status and product quality control are additional practical concerns outside medical supervision.
Bioavailability & pharmacokinetics
Drostanolone is formulated as an intramuscular ester to prolong systemic exposure. The propionate ester has a shorter half-life (approximately 1–2 days), requiring injections every other day to maintain stable blood levels. The enanthate ester is longer-acting and supports once- or twice-weekly dosing. As a DHT derivative, drostanolone has high androgen receptor affinity and is metabolized in peripheral tissues and the liver. Because it is non-aromatizable, it does not raise estradiol through aromatase conversion.
Populations studied
Randomized controlled trials of drostanolone for contemporary medical indications are absent. Historical oncology literature examined androgen therapy — including drostanolone — in postmenopausal women with advanced breast cancer; those studies are limited by small sample sizes, lack of modern comparators, and dated methodology. Contemporary safety and pharmacology data are drawn from AAS-user cohort studies and aggregate reviews, not drostanolone-specific trials.
Long-term safety and monitoring
Long-term AAS use is associated with adverse left ventricular remodeling, persistent lipid abnormalities, and psychiatric sequelae including dependence. Monitoring for anyone exposed to drostanolone should include periodic fasting lipid panels, liver enzymes, hematocrit/hemoglobin, blood pressure, and endocrine evaluation (testosterone, LH, FSH). HPT axis recovery after prolonged use is variable and may require endocrinology referral; some users experience hypogonadism that persists for months after cessation.
Legal status & ethical considerations
Drostanolone is a Schedule III controlled substance in the United States and similarly regulated in many other jurisdictions. It is prohibited in competition and out-of-competition by WADA and most major sports governing bodies. Obtaining it outside a prescription typically involves unregulated sources, introducing risks of adulteration, misdosing, and contamination. Medical providers encountering patients using drostanolone should approach the situation with a harm-reduction framework alongside standard clinical evaluation.
Compound variations
Drostanolone propionate
The propionate ester has a short half-life (approximately 1–2 days) and requires more frequent injections than the enanthate form.
Common use case
Shorter duration of exposure and faster clearance compared with longer esters.
Dosage note
Non-medical user reports cite 100–400 mg per week split across multiple injections (e.g., every other day). Not an evidence-based medical dose.
Drostanolone enanthate
The enanthate ester is longer-acting than the propionate form and supports once- or twice-weekly injection schedules.
Common use case
Less frequent injections for sustained blood levels; pharmacology is otherwise similar to the propionate ester.
Dosage note
Reported non-medical weekly totals are similar to propionate formulations but given in fewer injections per week.
Dosage and best practices
Dosage principles
- Historical medical regimens are obsolete and no modern standardized therapeutic dose exists for drostanolone.
- Non-medical user reports and AAS literature commonly describe drostanolone propionate at 100–400 mg per week (administered as 50–200 mg every other day), and drostanolone enanthate at equivalent weekly totals given once or twice weekly. These figures reflect observed use patterns, not evidence-based medical recommendations.
- Anyone exposed should obtain baseline and follow-up labs: serum total testosterone, LH, FSH, fasting lipid panel, liver enzymes (AST/ALT), hemoglobin/hematocrit, and blood pressure. Monitoring intervals should be individualized under medical supervision, but AAS monitoring literature commonly references baseline, 4–12 weeks after initiation, and post-cessation assessments.
Best practices
- Do not use drostanolone outside a licensed prescriber's recommendation. It is not a dietary supplement and carries legal and health risks.
- If exposure has occurred, establish baseline labs (testosterone, LH/FSH, lipids, liver enzymes, CBC, blood pressure) and repeat them periodically to detect HPT suppression, dyslipidemia, polycythemia, or hepatic injury.
- Disclose AAS use to healthcare providers — this affects interpretation of laboratory values and clinical management. Prolonged use followed by abrupt cessation may require endocrine follow-up for HPT axis recovery.
Literature and references
Pharmacology of anabolic steroids
British journal of pharmacology • 2008
A comprehensive review of the pharmacology, mechanisms, and health effects of anabolic-androgenic steroids, covering androgen receptor interactions and systemic effects.
Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?
Drug and alcohol dependence • 2008
Reviews psychiatric, neuroendocrine, and physical health consequences associated with long-term AAS use, drawing on observational evidence and case reports.
Effects of androgenic-anabolic steroids in athletes
Sports medicine (Auckland, N.Z.) • 2004
Summarizes known performance effects, side effects, and health risks of AAS use in athletic populations, including non-medical dosing patterns.
Drostanolone — compound summary
PubChem, National Library of Medicine • 0
Chemical and biological reference data for drostanolone, including molecular structure, synonyms, and links to pharmacological resources.
The World Anti-Doping Code — Prohibited List
World Anti-Doping Agency (WADA) • 2024
WADA's annually updated prohibited substances list, which classifies synthetic androgens including drostanolone as prohibited in and out of competition.
Common questions
Is Masteron a dietary supplement?
No. Masteron (drostanolone) is a synthetic anabolic-androgenic steroid, not a dietary supplement. It is a controlled substance in many jurisdictions and requires a licensed prescriber.
Does Masteron cause gynecomastia?
Drostanolone is non-aromatizable and carries a lower risk of estrogen-mediated gynecomastia than aromatizable androgens. However, co-administered drugs or pre-existing hormonal imbalances can still influence individual outcomes.
What medical uses does drostanolone have?
Historical uses included investigation for hormone-responsive advanced breast cancer, but drostanolone is not part of modern standard oncology practice. No current evidence-based medical indications have been established.
How long do effects and side effects last after stopping?
Pharmacologic effects wane as the ester clears (days to about two weeks depending on the ester). Endocrine suppression and adverse lipid changes may persist for weeks to months; HPT axis recovery is variable and sometimes prolonged. Endocrine follow-up is advisable after discontinuation of extended use.
What tests should I get if I have been exposed?
Obtain serum total testosterone, LH, FSH, fasting lipid profile, liver enzymes (AST/ALT), complete blood count (for hematocrit), and blood pressure at baseline and at follow-up intervals. Discuss results with a clinician experienced in endocrine effects of AAS.